ECCO 2026

IL-23 - is this the good-bye from systemic therapy?

Precision medicine - from a static to a dynamic system

Early treatment concepts with infliximab

IL-23: from real-world to special patient population

Update on upadacitinib vs. risankizumab after anti-TNF…

Deeper endpoints in clincial trials and RW

What is the best post-operative strategy in CD?

Long-term data on colorectal cancer risk in modern IBD…

Evolving landscape of anti-fibrotic therapy in IBD

Diet as prevention and early intervention in Crohn’s…

Stop of thiopurines in patients on subcutaneous…

Should we stop thiopurines in IBD patients who are…

Molecular signature–driven therapy

What is the best treatment approach in IBD?

Switching to subcutaneous infliximab is safe as a…

Molekulare Medizin als Wegweiser für…

Θα πρέπει να σταματήσουμε τις θειοπουρίνες σε ασθενείς…

Was ist der beste Therapieansatz bei CED?

LIR!C 10 yrs FUP: Is there a benefit for surgery?

Should we prevent or treat post-operative recurrence in…

Do we need immediate postoperative prophylaxis?

JAK–STAT inhibition as a therapeutic approach for…

Early use of infliximab positively influences longterm…

Top-down vs. step-up therapy in CD

JAK-STAT Hemmung zur Fistel-Therapie

Top-down vs. Step-up Therapie beim Morbus Crohn

Faut-il prévenir ou traiter la récidive postopératoire…

Is onmiddellijke postoperatieve preventie nodig?

LIR!C — suivi 10 ans: bénéfice de la chirurgie?

Steroid sparing effect of filgotinib in UC

Pouch surgery: only for expert centers

Treat-2-target strategy in UC

Long term outcomes after appendicectomy in UC (5 year…

Combination therapy with tofacitinib and…

Effetto steroid-sparing di filgotinib nella colite…

ASUC: Derde‑lijn­therapie slimmer inzetten

Tofacitinib-Steroid-Kombination bei ASUC

Pouchchirurgie: enkel voor expertisecentra

Resultados a largo plazo tras apendicectomía en colitis…

The risk of colorectal neoplasia in IBD

Obefazimod as antifibrotic agent

Langetermijn data van IL‑23 inhibitoren

Risque de cancer colorectal dans les MICI

Histo-endoscopic outcomes of upadacitinib in CD

Guselkumab may improve and prevent extraintestinal…

Outside the gut - efficacy uf guselkumab in…

UPA vs RISA in Crohn’s disease – a decision dilemma

Ustekinumab is effective and safe for paediatric…

Το ustekinumab είναι αποτελεσματικό και ασφαλές σε…

Nicht nur im Darm – Wirksamkeit von Guselkumab bei…

Guselkumab a objawy pozajelitowe

UPA vs RISA w chorobie Leśniowskiego-Crohna – sztuka…

Etrasimod in the milder moderate UC patients

Histo-endoscopic outcomes of guselkumab in UC

Short term transmural healing detected by US in CD…

Efficacy and safety of vedolizumab + upadacitinib as…

Etrasimod efficacy in mildly-to-moderately active UC…

Vedolizumab combined with upadacitinib vs Vedolizumab…

Short-term effectiveness and safety of Mirikizumab in…

Early symptomatic response with IL-23 blockers

Long-term efficacy and safety of risankizumab in UC

Does colectomy reduce the risk of death in UC?

Mirikizumab is able to induce disease clearence in…

Est-ce que la colectomie réduit le risque de décès dans…

Efectividad y seguridad a corto plazo de Mirikizumab en…

Vedolizumab combinado con upadacitinib vs Vedolizumab…

Efficacia di Etrasimod in pazienti affetti da colite…

Efficacia e sicurezza di vedolizumab + upadacitinib…

Valutazione a breve termine della guarigione…

Efficacia e sicurezza a lungo termine di risankizumab…

Impact of icotrokinra on biomarkers in UC

Ontunisertib - ALK5 blockage in fistulizing CD

B-cells step into the spotlight

Cytotoxic CD4+ accumulate in the UC but not CD mucosa…

The STENOVA Trial. Ontunisertib shows promising results…

Appendectomy - a new therapeutic option in UC

Icotrokinra and systemic inflammatory burden in UC

L’accumulo di cellule citotossiche CD4+ caratterizza la…

AGMB-129, Ontunisertib, nueva terapia para pacientes…

Ikotrokinkra a stan zapalny w colitis ulcerosa

Ontunisertib – ALK5-Blockade bei fistulierendem Morbus…

Impact de l’icotrokinra sur les biomarqueurs dans la…

תאי B במרכז העניינים

Η μελέτη STENOVA: Το ontunisertib δείχνει υποσχόμενα…

AI endoscopic reads in acute severe UC change the…

IBDMED going global!

IBDMED מעבר לאזור הים התיכון